D-galactosamine hydrochloride | 14257-79-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: D-galactosamine hydrochloride
• 英文别名: (2R,3R,4R,5R,6R)-3-Amino-6-(hydroxymethyl)tetrahydro-2H-pyran-2,4,5-triol hydrochloride；(2R,3R,4R,5R,6R)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;hydrochloride
• CAS: 14257-79-5
• 化学式: C₆H₁₃NO₅*ClH
• 分子量: 215.634
• InChiKey: QKPLRMLTKYXDST-WYRLRVFGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.83
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  116
• 氢给体数：
  6
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  D-galactosamine hydrochloride 在 吡啶 、 scandium tris(trifluoromethanesulfonate) 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 2.0h， 生成 (2R,3R,4R,5R,6R)-5-acetamido-2-(acetoxymethyl)-6-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)tetrahydro-2H-pyran-3,4-diyl diacetate
  参考文献：
  名称：

  [EN] TARGETED COMPOSITIONS
  [FR] COMPOSITIONS CIBLÉES

  摘要：

  公开号：

  WO2018191278A3
• 作为产物：
  描述：

  2-amino-2-deoxy-α-D-galactopyranose hydrochloride 生成 D-galactosamine hydrochloride
  参考文献：
  名称：

  PISHCHUGIN, F. V.;SHARSHENALIEVA, Z. SH.;DAKENOVA, N. S., IZV. AN KIRGSSR. XIM.-TEXNOL. I BIOL. N.,(1989) N, S. 14-19

  摘要：

  DOI：

文献信息

• [EN] TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS<br/>[FR] COMPOSITIONS DE CONJUGUÉS D'ACIDES NUCLÉIQUES CIBLÉS
  申请人：PROTIVA BIOTHERAPEUTICS INC

  公开号：WO2017177326A1

  公开（公告）日：2017-10-19

  The invention provides conjugates that comprise a targeting moiety, a nucleic acid, and optional linking groups as well as synthetic intermediates and synthetic methods useful for preparing the conjugates. The conjugates are useful to target therapeutic nucleic acids to the liver and to treat liver diseases including hepatitis (e.g. hepatitis B and hepatitis D).

  这项发明提供了包括靶向基团、核酸和可选连接基团的共轭物，以及用于制备这些共轭物的合成中间体和合成方法。这些共轭物可用于将治疗性核酸靶向肝脏，并用于治疗包括肝炎（如乙型肝炎和丙型肝炎）在内的肝脏疾病。
• MEDICINAL PREPARATION
  申请人：TORAY INDUSTRIES, INC.

  公开号：EP1787661A1

  公开（公告）日：2007-05-23

  A pharmaceutical preparation has a ligand structure specifically recognizing a target site and an amphiphilic compound having a hydrophobic or amphiphilic group. The pharmaceutical preparation employs an amphiphilic compound of specific structure obtained by introducing a chained hydrophilic group with an appropriate flexibility, and thus becomes a fine particle suited for drug targeting. The pharmaceutical preparation is expected to give a prolonged pharmacological effect. A particulate preparation exhibiting a remarkable site targeting property can be formed. Further, according to the selection of matrix forming material, the drug releasing property can be controlled.

  一种药物制剂具有特异性识别靶位点的配体结构和具有疏水或两性亲和性基团的两性化合物。该药物制剂采用通过引入具有适当柔韧性的链状亲水基团获得的特定结构的两性化合物，因此成为适用于药物靶向的细颗粒。 预计该药物制剂将产生持久的药理效应。可以形成具有显著靶向性能的颗粒制剂。此外，根据基质形成材料的选择，可以控制药物释放性能。
• FORMING POROUS SCAFFOLD FROM CELLULOSE DERIVATIVES
  申请人：Yue Zhilian

  公开号：US20130005945A1

  公开（公告）日：2013-01-03

  Scaffold comprises a polymer defining macropores and comprising hydroxypropylcellulose partially substituted by a substituent comprising a self-crosslinkable group, which is crosslinked through the self-crosslinkable group. The macropores have an average pore size larger than 50 microns and are at least partially interconnected. In one method, bicontinuous emulsion comprising a continuous aqueous phase and a continuous polymer phase is formed. The polymer phase comprises hydroxypropylcellulose partially substituted by a substituent comprising a self-crosslinkable group, and is crosslinked through the self-crosslinkable group to form a polymer defining at least partially interconnected pores. In another method, phase separation is induced in a solution comprising a polymer precursor and water to form a bicontinuous emulsion comprising a continuous polymer phase and a continuous aqueous phase. The polymer precursor comprises a self-crosslinkable group and is crosslinked through the self-crosslinkable group in the emulsion to form a polymer defining at least partially interconnected macropores.

  支架包括一种聚合物，其定义了大孔隙，并包括部分被含有自交联基团的取代基取代的羟丙基纤维素，通过自交联基团进行交联。这些大孔隙的平均孔径大于50微米，并且至少部分相互连接。在一种方法中，形成了由连续水相和连续聚合物相组成的双连续乳液。聚合物相包括部分被含有自交联基团的取代基取代的羟丙基纤维素，并通过自交联基团进行交联，形成定义至少部分相互连接的孔隙的聚合物。在另一种方法中，在包含聚合物前体和水的溶液中诱导相分离，形成了由连续聚合物相和连续水相组成的双连续乳液。聚合物前体包括自交联基团，并在乳液中通过自交联基团进行交联，形成定义至少部分相互连接的大孔隙的聚合物。
• HF-Induced Intramolecular <i>C</i>-Arylation and <i>C</i>-Alkylation/Fluorination of 2-Aminoglycopyranoses
  作者：Nicolas Probst、Amélie Martin、Jérôme Désiré、Agnès Mingot、Jérôme Marrot、Yves Blériot、Sébastien Thibaudeau

  DOI：10.1021/acs.orglett.7b00003

  日期：2017.3.3

  Internal C-aryl and C-alkyl glycosides derived from 2-aminoglycopyranoses have been synthesized, exploiting a HF-mediated stereoselective intramolecular glycosylation. These conditions are compatible with acetate protecting groups and allow introduction of aromatics with various electronic distributions at the anomeric position. This strategy also provides straightforward entry to original fluorinated

  利用HF介导的立体选择性分子内糖基化，已经合成了衍生自2-氨基糖基葡萄糖的内部C-芳基和C-烷基糖苷。这些条件与乙酸酯保护基相容，并允许引入在端基异构位置具有各种电子分布的芳族化合物。该策略还通过串联内部C-糖基化/氟化反应（从2- N-烯丙基/炔丙基糖吡喃糖开始），直接进入原始的氟化糖-氮杂二环杂化物。所有环化均以1,2-顺式立体控制的方式进行。
• [EN] POLYNUCLEOTIDE CONSTRUCTS HAVING AN AUXILIARY MOIETY NON-BIOREVERSIBLY LINKED TO AN INTERNUCLEOSIDE PHOSPHATE OR PHOSPHOROTHIOATE<br/>[FR] CONSTRUCTIONS POLYNUCLÉOTIDIQUES COMPORTANT UNE FRACTION AUXILIAIRE LIÉE DE FAÇON NON BIORÉVERSIBLE À UN PHOSPHATE INTERNUCLÉOSIDIQUE OU À UN PHOSPHOROTHIOATE
  申请人：SOLSTICE BIOLOGICS LTD

  公开号：WO2017100461A1

  公开（公告）日：2017-06-15

  The invention features a hybridized polynucleotide construct including a passenger strand, a guide strand loadable into a RISC complex, and one or more auxiliary moieties. At least one of the auxiliary moieties is non-bioreversibly linked to an internucleoside phosphate or phosphorothioate in the passenger strand. The invention further features methods of delivery a polynucleotide construct to a cell and methods of reducing the expression of a protein in a cell. The methods typically involve contacting the cell with the hybridized polynucleotide construct.

  该发明涉及一种杂交多核苷酸构造，包括一个载体链、一个可装载到RISC复合物中的引导链，以及一个或多个辅助基团。至少一个辅助基团与载体链中的一个核苷酸间磷酸酯或磷硫酸酯非可逆地连接。该发明还涉及将多核苷酸构造递送至细胞的方法以及减少细胞中蛋白质表达的方法。这些方法通常涉及将细胞与杂交多核苷酸构造接触。